Compass Pathways Stock

Compass Pathways Revenue

The revenue of Compass Pathways (CMPS) as of Jul 27, 2026.

Revenue

0.00USD

Last updated:

In 2026, Compass Pathways's sales reached 0.00 USD, a % difference from the 0.00 USD sales recorded in the previous year.

The Compass Pathways Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (M USD)
GROSS MARGIN (%)
Date
REVENUE (M USD)
GROSS MARGIN (%)
Jan 1, 2023
0.00 base
0.00 base
Jan 1, 2024
0.00 base
0.00 base
Jan 1, 2025
0.00 base
0.00 base
Jan 1, 2026 (e)
0.00 base
0.00 base
Jan 1, 2027 (e)
61.21 base
-0.35 base
Jan 1, 2028 (e)
159.60 base
-0.14 base
Jan 1, 2029 (e)
399.76 base
-0.05 base
Jan 1, 2030 (e)
770.28 base
-0.03 base
YEARREVENUE (M USD)GROSS MARGIN (%)
2030 est 770.28-0.03
2029 est 399.76-0.05
2028 est 159.60-0.14
2027 est 61.21-0.35
2026 est --
2025 --
2024 --
2023 --
2022 --
2021 --
2020 --
2019 --
2018 --
Access this data via the Eulerpool API

Compass Pathways Revenue

Compass Pathways Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-136.92 M USD
-118.46 M USD
Jan 1, 2024
0.00 USD
-178.21 M USD
-155.12 M USD
Jan 1, 2025
0.00 USD
-179.04 M USD
-287.86 M USD
Jan 1, 2026 (e)
0.00 USD
-221.16 M USD
-112.93 M USD
Jan 1, 2027 (e)
61.21 M USD
-226.83 M USD
-123.15 M USD
Jan 1, 2028 (e)
159.60 M USD
-189.88 M USD
-171.34 M USD
Jan 1, 2029 (e)
399.76 M USD
91.16 M USD
-177.13 M USD
Jan 1, 2030 (e)
770.28 M USD
381.41 M USD
-39.36 M USD

Compass Pathways Margins

Compass Pathways stock margins

The Compass Pathways margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Compass Pathways. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Compass Pathways.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025
0.00 %
- %
- %
Jan 1, 2026 (e)
0.00 %
- %
- %
Jan 1, 2027 (e)
0.00 %
-370.60 %
-201.20 %
Jan 1, 2028 (e)
0.00 %
-118.97 %
-107.36 %
Jan 1, 2029 (e)
0.00 %
22.80 %
-44.31 %
Jan 1, 2030 (e)
0.00 %
49.52 %
-5.11 %

Compass Pathways Stock analysis

What does Compass Pathways do? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Compass Pathways's Sales Figures

The sales figures of Compass Pathways originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Compass Pathways’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Compass Pathways's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Compass Pathways’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Compass Pathways stock

On Eulerpool you can find the complete historical development of The revenue Compass Pathways since 2006 – with annual values, charts, and detailed analysis.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Compass Pathways

All Key Metrics — Compass Pathways